Abstract-Sites of the inhibitory action of antiallergic drugs (azelastine, oxatomide, tranilast, repirinast and amlexanox) on human neutrophils were investigated by measuring leukotriene B4 formation, arachidonic acid release and superoxide generation. Results obtained in this study were as follows: (1) Formations of leukotriene B4 by neutrophils activated with a calcium ionophore (A23187) were effectively inhibited by all types of antiallergic drugs examined here, although the required concentrations were within a range of 20-200 /tM. (ii) Releases of arachidonic acid from activated cells were diminished by azelastine and oxatomide that were classified as basic antiallergic drugs. On the contrary, acidic antiallergic agents including repirinast, amlexanox and tranilast enhanced the arachidonic acid liberation. (iii) Generations of superoxide from neutrophils activated with either phorbol 12-myristate 13-acetate or n-formyl-methionyl-leucyl-phenylalanine were effectively diminished only by the basic antiallergic drugs.
In the process of allergic reactions, a variety of substances are released as "chemical mediators"
and these include histamine, serotonin, bradykinin and leukotrienes (LTs) (1) . Leukotrienes including LTB4, LTC4 and LTD4 and LTE4 can be produced in mast cells, basophils as well as neutrophils, and they are released from human or guinea pig lungs upon immunological challenge (2) . Since they possess a potent vasoconstricting activity and cause contraction of bronchial air way (3, 4) , LTs may play an important role in immediate hypersensitivity responses as mediators of allergic bronchocontraction and vascular per meability (5) . LTB4 which can be produced by human neutrophils is a potent chemotactic and aggregating agent for many types of cells, and it may have an important role in inflam mation and tissue damage (6, 7) .
It is widely known that all of the pros taglandins as well as LTs can be produced from arachidonic acid, which could be re leased from membrane phospholipids by phospho!ipase A2 (8) (9) (10) . For LTs formation, arachidonic acid is converted to 5-hydroxy eicosatetraenoic acid by enzyme lipoxy genase and then further enzymatically trans formed to LTs B4, C4, D4 and E4 (11) . There fore, there are at least two stage where drugs can influence the formation of LTs: (1) the liberation of arachidonic acid from phos pholipids and (ii) the catabolic steps which convert the arachidonic acid to LTs. Thus, the development of inhibitors of LT release in vivo became of therapeutic relevance, and such drugs are now classified as "antiallergic agents" (12) . The first representative of this category of antiallergic agent, disodium chromoglycate, was reported in 1967 (13) , and many drugs such as ketotifen and azelastine are now being used clinically for treatments of various allergic diseases in cluding bronchial asthma.
Although their chemical structures are quite different as seen in Fig. 1 , the agents may be classified into two groups: (1) the basic antiallergic drugs (azelastine and ox atomide) containing amines in their structure and (ii) the acidic antiallergic drugs (re pirinast, amlexanox and tranilast) which have carbonic acid in their molecules. Furthermore, the antiallergic properties are different among the various types of agents in which the basic drugs are known to act not only as an inhibitor of LT release but also has antihistaminic ac tivity (14) . On the other hand, the acidic agents were developed on the basis of ob servations that DSCG (disodium cromogly cate), bicalein and caffeic acid are inhibitors of chemical mediator release (12, 15) . We have previously shown that superoxide generation, arachidonic acid release as well as changes of membrane potential were sup pressed by one of the basic antiallergic agents, azelastine (16) (17) (18) . In this study, we attemped to compare the inhibitory effects of antial lergic drugs on the release of arachidonic acid, leukotriene B4 and superoxide from ac tivated human neutrophils to clarify the action sites of the various basic and acidic anti allergic drugs.
Materials and Methods

Preparation
of neutrophils: Human neu trophils were separated from the blood of healthy volunteers.
Preparations containing 90-95% polymorphonuclear leukocytes were obtained by the dextran sedimentation of the whole blood followed by Ficoll-Hypaque gradient centrifugation (19) . Contaminating erythrocytes were removed by hypotonic !ysis. After restoring the osmolarity, the cells were washed twice with Gey's balanced salt solu tion containing 0.1% BSA and 10 mM H EPES, pH 7.4 (modified Gey's solution) and resuspended in an appropriate buffer. Measurement of leukotriene production: Neutrophils were resuspended (106 cells/ml) in Dulbecco's phosphate buffered saline, pH 7.4. The cell suspension was preincubated with or without drugs at 37'C for 5 min. The reaction was started by the addition of 2 tiM A231 87 and carried out for a further 2 min. At the end of the incubation period, the same volume of ice cold buffer was added. After centrifugation (1500xg, 10 min), the super natant was used for the assay of leukotriene B4. Leukotriene B4 was measured by using a leukotriene B4 radioimmunoassay kit (Amer sham). The value of A23187-induced leu kotriene B4 production from human neu trophils was 20.5±2.6 nmoles/106 cells in 2 min. Measurement of arachidonic acid release: Arachidonic acid release from human neu trophils was measured by a previously de scribed method (20) . Neutrophils were re suspended in modified Gey's solution at the concentration of 1 X 107 cells/ml. The cell suspension was incubated with [3H] arachidonic acid (2.96 TBq/mmoles, NEN) in order to incorporate the radiolabelled ar achidonic acid into neutrophils at the final concentration of 9.25 KBq/ml at 37 °C for 10 min. The incorporation was terminated by the addition of 5 volumes of ice cold buffer and centrifuged (400xg, 2 min). The pellet was washed twice with modified Gey's solution and resuspended in the same buffer to give a final concentration of 1 X 10' cells/ml (58026± 12514 dpm/5 X 106 cells). The labeled cells (5X 106 cells/0.5 ml) were preincubated with or without drugs at 37'C for 5 min. The re action was started by the addition of 2 t M of A231 87 and then carried out for a further 10 min before termination by the addition of 1.75 ml of methanol : chloroform (2:1, vol./vol.). Extraction and separation of lipids were car ried out according to the method described by Bligh and Dyer (21) . The chloroform extract was evaporated under a stream of nitrogen, and the residue was spotted on a TLC plate (silica gel, Merk) and developed in petroleum ether : diethyl ether : acetic acid (80:20:1, vol./vol.). Spots detected by iodine vapor were scraped into a counting vial, and the radioactivity was measured by a liquid scintil lation counter after the addition of 10 ml of Scintisol (Wako Pure Chemical Indust.) to each vial. The value of A23187-stimulated release of arachidonic acid from neutrophils was 8245±1880 dpm. In the absence of stimuli, the control value was 2061 ±343 dpm.
Measurement of superoxide anion pro duction: Superoxide anion production was measured as described previously (20) 
Results
To examine the inhibitory effects of cur rently developed antiallergic drugs on neu trophils, we employed azelastine, oxatomide, tranilast, repirinast and amlexanox which are classified as "Inhibitors of chemical mediator release". Human neutrophils were isolated and activated by A23187 and PMA or FM LP for the assays of the arachidonic acid release or LTB4 formation and superoxide generation, respectively. The effects of various antiallergic drugs on arachidonic acid release and LTB4 production are summarized in Table 1 where the inhibitory effects are expressed as a percent of remaining activity from a control activity obtained from the stimulated neu trophils in the absence of drugs. A shown in the Methods section, 100% radioactivities of the arachidonic acid released was 6184± 1717 dpm/5 X 106 cells. In the presence of drugs, the cells were preincubated for 5 min before the addition of the metabolic stimuli (A231 87) and incubated for a further 10 and 2 min for the arachidonic acid release and LTB4, respectively.
As seen in Table 1 Control values (100%) of leukotriene B4 production and arachidonic acid release was 20.5±2.6 nmoles/ 1011 cells in "min and 6184±1717 dpm/5x106 cells in 10 min, respectively. Each value represents the mean±S.D. of 3 or 4 independent experiments.
Significantly different from the control: ***P<0.01, **P<0 .02, *P<0.05.
oxatomide
(IC50<50 ,uM)<azelastine and repirinast<amlexanox<tranilast (IC50>100 tiM). On the other hand, the releases of arachidonic acid as a precursor of LTB4 were effectively diminished only by the basic an tiallergic drugs, such as azelastine and ox atomide, but the acidic agents including tranilast, amlexanox and repirinast up to 200 ,aM failed to inhibit the liberation of fatty acid. In fact, the acidic antiallergic drugs, especially amlexanox and repirinast rather enhanced the arachidonic acid release even at lower con centrations (20 ,uM) . Since a similar acti vation phenomena was observed in the superoxide generation from neutrophils, we will discuss this further in a later section.
These data clearly indicate that the basic drugs inhibited both arachidonic acid release as well as LTB4 formation, whereas the acidic agents inhibited only the LTB4 formation. Furthermore, the effects of antiallergic drugs on superoxide generation from neutrophils stimulated by PMA were compared with that on the LTB4 formation by A231 87. As shown in Fig. 2 , the results were similar to those seen in Table 1 arachidonic acid release and formation of LTs. Especially, azalastine almost completely inhibited the superoxide generation even at lower concentration (20 flM). On the con trary, all of the acidic drugs up to 100 aM failed to inhibit the PMA stimulated super oxide generation.
A slight activation of the superoxide generation was observed with the PMA activated neutrophils in the presence of acidic drugs. A striking enhancement of the superoxide generation was found neutro phils were activated by chernotactic factor (FMLP) with repirinast as demonstrated in Fig. 3 . Over 200% of the superoxide produc tion was observed when FM LP was chal lenged to the incubation medium in the presence of 100 ,rcM of repirinast. The en hancement of the respiratory burst by re pirinast was seen even at lower concentration (20 W), but it had only a slight effect on PMA stimulated superoxide generation. Al though the degrees were not identical, activa tions were commonly observed in arachidonic acid release as well as superoxide generation by acidic antiallergic drugs. In contrast, ef fective inhibition of the superoxide generation by azelastine was observed regardless of the type of metabolic stimuli employed.
Discussion
Although mast cells and basophils are known to play central roles in the immunolo gical responses of human allergic diseases, the current therapy for allergies emphasizes, the action of compounds of LT release (22, 23) , and one of the major suppliers of the archidonic acid metabolites is neutrophils. Therefore, it is worth-while to examine the effects of various antiallergic drugs on the metabolic responses of human neutrophils.
In previous studies, we have demonstrated that metabolic bursts of rabbit polymorphonu clear leukocytes such as superoxide genera tion and arachidonic acid releases were effec tively diminished by the newly developed antiallergic drug, azelastine (17, 20) . In this study, attempts were made to examine five representative new drugs including oxa tomide, azelastine, tranilast, repirinast and amplexanox on superoxide generation, arachi donic acid release and LTB4 formation from the stimulated human neutrophils. The results obtained here suggested that the drugs mentioned above can be classified into two groups according to how they inhibit the metabolic activations as well as the chemical structures of the agents. That is, the amine containing antiallergic drugs inhibit three kinds of metabolic bursts including super oxide, arachidonic acid and LTB4 formations, but the carbonic acid containing agents inhibited only the production of LTB4. The initiation of arachidonic acid cascade in neutrophils starts with an increase of in tracellular calcium concentration due to either extracellular entry or mobilization from calci um storage (24) . Under our experimental con ditions. a calcium ionophore increases in tracellular calcium concentration (25) , so that phospholipase A2 or glyceride lipase liberates fatty acids from phospholipids and then lipoxigenase systems convert arachidonic acid to LTs (26, 27) .
The present results suggest that the libera tion of arachidonic acid from phospholipids is inhibited by the basic antiallergic agents, and catabolic steps which convert arachidonic acid to LTs are inhibited by the acidic antial lergic drugs. The superoxide generation was also effectively diminished only by the basic drugs indicating that there was a close rela tionship between the inhibitory effects on the phospholipase A2 activation and the plasma membrane located NADPH oxidase. In other words, it is likely that the basic antiallergic drugs may inhibit plasma membrane located enzymes such as phospholipase A2 and NADPH oxidase. In this respect, there is a possibility that the inhibition of these enzymes may be due to changes in the local charge of membranous proteins. This assumption can be supported with the results demonstrated by Miyahara et al. which suggest that a charged moiety of the neutrophils play a key role in metabolic stimulation (28, 29) . They showed that the inhibition and activation of super oxide generation by leukocytes manipulated by anionic and cationic agents. Therefore, the initiation of the respiratory burst, which is generally accepted as linked to protein kinase C activation (30) , might be related to the presence of a net charge on the plasma membrane.
As shown in Table 1 and Fig. 3 , the acidic antiallergic drugs activate the arachidonic acid release as well as superoxide generation, although the degrees of the effects are quite different. The most striking activation of superoxide generation is seen with the com bination of FM LP and repirinast. Presumably, this could be largely due to the anionic prop erty of repirinast, which may mobilize the signal transport proteins as well as mem branous enzymes. However, PMA can pene trate into the cytosol where regulatory pro teins are phosphorylated.
So that, the en hancement by repirinast with PMA are less than the activation seen by FMLP. (Further details are under investigation in our labora tory.) The anionic property of the acidic agents may, therefore, enhance the activation process or mobilization of the plasma mem brane located enzymes such as NADPH oxi dase and phospholipase A2. On the other hand, the inhibition of arachidonic acid release and superoxide generation by the basic drugs could be clue to the cationic property of the antiallergic agents.
Although the roles of fatty acid liberated in the activation process of superoxide genera tion have been a matter of debate, recent investigation show that there is a possibility that the arachidonic acid is essential for the activation of NADPH oxidase in the plasma membrane (31, 32) . These observations indicate that the arachidonic acid liberated by phospholipase A2 is playing a key role in the metabolic burst of PMNs. The inhibition of the lipase activity by agents may result in the inhibition of superoxide generation.
In any case, further investigations on the initiation process of the metabolic activation are neces sary to discuss the relationship between superoxide generation and arachidonic acid release from PMNs.
To clarify the precise mechanisms involved, further studies are currently being performed using the H L60 cell line in our laboratories and the relevance of the mechanisms under in vivo conditions should be examined for therapeutic uses.
